Tempus AI (NASDAQ:TEM) Stock Price Down 2.3% – Time to Sell?

Tempus AI, Inc. (NASDAQ:TEM) shares fell 2.3% during trading on Thursday . The company traded as low as $57.66 and last traded at $60.81. 8,502,496 shares were traded during mid-day trading, a decline of 43% from the average session volume of 14,817,857 shares. The stock had previously closed at $62.26.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. downgraded Tempus AI from an “overweight” rating to a “neutral” rating and raised their price target for the company from $50.00 to $55.00 in a research report on Tuesday. Piper Sandler reissued a “neutral” rating and set a $70.00 price objective (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Bank of America upped their target price on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. TD Cowen reissued a “buy” rating and set a $74.00 price target (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Finally, Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and upped their price objective for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Tempus AI has a consensus rating of “Moderate Buy” and a consensus target price of $60.55.

Tempus AI Stock Performance

The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The stock has a 50-day moving average price of $51.84 and a two-hundred day moving average price of $52.24.

Insider Transactions at Tempus AI

In other news, EVP Andrew Polovin sold 51,504 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total value of $2,183,254.56. Following the transaction, the executive vice president now directly owns 246,085 shares in the company, valued at $10,431,543.15. This trade represents a 17.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO James William Rogers sold 31,780 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $82.33, for a total value of $2,616,447.40. Following the sale, the chief financial officer now owns 189,320 shares of the company’s stock, valued at approximately $15,586,715.60. This trade represents a 14.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,583,467 shares of company stock valued at $130,542,311 in the last ninety days.

Hedge Funds Weigh In On Tempus AI

Several institutional investors have recently made changes to their positions in the business. First Horizon Advisors Inc. bought a new stake in Tempus AI during the third quarter valued at about $30,000. Operose Advisors LLC purchased a new position in shares of Tempus AI during the 4th quarter valued at $25,000. Farther Finance Advisors LLC bought a new position in Tempus AI in the 4th quarter worth $34,000. Prestige Wealth Management Group LLC increased its stake in Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after buying an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC purchased a new stake in Tempus AI in the 4th quarter worth $49,000. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.